HDAC1 and non-small cell lung carcinoma: Our finding not only identified a novel dual-targeting compound to reverse acquired resistance to cisplatin in NSCLC, but also demonstrated that HDAC1 combined with OAZ1 might be a valuable response biomarker for cisplatin treatment.